Cell Therapy Biomanufacturing: Global Markets

Report Highlights

The global market for cell therapy biomanufacturing is expected to grow from $9.7 billion in 2024 and is projected to reach $16.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2024 to 2029.

Report Includes

• 17 data tables and 25 additional tables
• Analysis of the global markets for cell therapy biomanufacturing
• Analyses of global market trends, with market revenue data from 2022, estimates for 2023, forecasts for 2024 and projected CAGRs through 2029
• Estimates of the current market size and revenue prospects, along with a market share analysis by product type, application, end user and region
• Facts and figures pertaining to the market dynamics, technological advances, product launches, regulatory scenarios, and the expected impact of macroeconomic factors
• An analysis of patents and emerging technologies
• Overview of sustainability trends and ESG developments in the industry, with a focus on consumer attitudes, companies’ ESG score rankings and their ESG practices
• An analysis of the industry structure, including companies’ market shares, merger and acquisition activity, and venture funding
• Profiles of the leading companies, including Thermo Fisher Scientific Inc., Bristol-Myers Squibb Co., Lonza, Merck KGaA, andBioSenic SA

Report Scope

This report discusses the key trends shaping the global cell therapy biomanufacturing market, exploring factors that drive or hinder growth while providing valuable insights for stakeholders and potential newcomers. It examines R&D investment, heightened competition, and emerging technologies steering market dynamics. Moreover, the report assesses how advancements, product launches, and governmental initiatives impact future market trajectories. It also scrutinizes corporate actions like mergers, acquisitions, and partnerships. Additionally, the report evaluates the efficacy of various strategies in light of evolving technologies, intensifying competition, and shifting consumer demands.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Christian Goodwin, MD, MPH, is a resident physician at Duke University. He completed his undergraduate degree at the University of Virginia. He obtained his MPH at the University of Liverpool as a US-UK Fulbright Scholar while serving as a visiting researcher at the Palliative Care Institute Liverpool. He obtained his MD from the University of North Carolina as a Blanchard Scholar. Christian has expertise in health systems innovation, public health research, geriatrics, and psychiatry.